Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada; Kidney Clinical Research Unit, London Health Sciences Centre, London, Ontario, Canada; Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Am J Kidney Dis. 2014 Mar;63(3):464-78. doi: 10.1053/j.ajkd.2013.08.023. Epub 2013 Oct 30.
Advantages of the arteriovenous fistula (AVF), including long patency and few complications, were ascertained more than 2 decades ago and may not apply to the contemporary dialysis population.
Systematic review and meta-analysis. Estimates were pooled using a random-effects model and sources of heterogeneity were explored using metaregression.
SETTING & POPULATION: Patients treated with long-term hemodialysis using an AVF.
English-language studies indexed in MEDLINE between 2000 and 2012 using prospectively collected data on 100 or more AVFs.
Age, AVF location, and study location.
Outcomes of interest were primary AVF failure and primary and secondary patency at 1 and 2 years.
7,011 citations were screened and 46 articles met eligibility criteria (62 unique cohorts; n = 12,383). The rate of primary failure was 23% (95% CI, 18%-28%; 37 cohorts; 7,393 AVFs). When primary failures were included, the primary patency rate was 60% (95% CI, 56%-64%; 13 studies; 21 cohorts; 4,111 AVFs) at 1 year and 51% (95% CI, 44%-58%; 7 studies; 12 cohorts; 2,694 AVFs) at 2 years. The secondary patency rate was 71% (95% CI, 64%-78%; 10 studies; 11 cohorts; 3,558 AVFs) at 1 year and 64% (95% CI, 56%-73%; 6 studies; 11 cohorts; 1,939 AVFs) at 2 years. In metaregression, there was a significant decrease in primary patency rate in studies that started recruitment in more recent years.
Low quality of studies, variable clinical settings, and variable definitions of primary AVF failure.
In recent years, AVFs had a high rate of primary failure and low to moderate primary and secondary patency rates. Consideration of these outcomes is required when choosing a patient's preferred access type.
动静脉瘘(AVF)的优势,包括长期通畅和并发症少,早在 20 多年前就已确定,但可能不适用于当代透析人群。
系统评价和荟萃分析。使用随机效应模型汇总估计值,并使用荟萃回归探索异质性来源。
接受长期血液透析治疗的患者,使用 AVF。
2000 年至 2012 年期间在 MEDLINE 上发表的英语文献,使用前瞻性收集的 100 例或更多 AVF 数据。
年龄、AVF 位置和研究地点。
筛选了 7011 条引文,46 篇文章符合入选标准(62 个独特队列;n=12383)。主要 AVF 失败的发生率为 23%(95%CI,18%-28%;37 个队列;7393 个 AVF)。当包括主要失败时,1 年时的主要通畅率为 60%(95%CI,56%-64%;13 项研究;21 个队列;4111 个 AVF),2 年时为 51%(95%CI,44%-58%;7 项研究;12 个队列;2694 个 AVF)。2 年时的次级通畅率为 71%(95%CI,64%-78%;10 项研究;11 个队列;3558 个 AVF)。在荟萃回归中,在最近几年开始招募的研究中,主要通畅率显著下降。
研究质量低、临床环境不同、以及主要 AVF 失败的定义不同。
近年来,AVF 的主要失败率较高,主要和次要通畅率较低或中等。在选择患者首选的血管通路类型时,需要考虑这些结果。